Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

Shirish Gadgeel*, Alice T. Shaw, Fabrice Barlesi, Lucio Crino, James Chih-Hsin Yang, Anne-Marie C. Dingemans, Dong-Wan Kim, Filippo de Marinis, Mathias Schulz, Shiyao Liu, Ravindra Gupta, Ahmed Kotb, Sai-Hong Ignatius Ou

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalBritish Journal of Cancer
Volume118
Issue number1
DOIs
Publication statusPublished - 9 Jan 2018

Keywords

  • alectinib
  • ALK positive
  • central nervous system
  • cumulative incidence rates
  • disease progression
  • non-small-cell lung cancer
  • phase II
  • CELL LUNG-CANCER
  • OPEN-LABEL
  • CRIZOTINIB

Cite this